India ranks 6th in the Asia-Pacific region for the Italian super luxury carmaker.
Dealers said the discounts this March are higher than the same month in the previous year.
Major Indian carmakers are preparing for sluggish domestic PV sales growth of just 1-2 per cent in FY26.
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
With India's EV penetration at just 2.5 per cent, the market presents an opportunity -- provided Tesla gets its pricing right.
In 2024 alone, South India saw the highest rise in sales in the luxury segment, with Tamil Nadu reportedly registering a 19.3 per cent increase in premium car registrations from 2022-23
Indian pharmaceutical companies may have units abroad as part of "distributed manufacturing" across various locations, according to industry veterans. This may come about over the next five to 10 years.
Firodia talked about his plans for the EV-components business, and the components business at large for the group
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
The Indian automotive market offers around 1 million units annual volume opportunity at a price above $23,000.
Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.
Tesla needs to either sell the same models with reduced features to lower the cost for Indian market, or incur losses.
'If the Bill and Melinda Gates Foundation cuts funds, there could be more impact.'
Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.
After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.
Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?
'We have to be prepared for the larger disruption that is likely to take place.'
Water samples from different parts of Pune have been sent to the public health laboratory for chemical and biological analysis.
As battery prices drop, early customers of Tata Motors, which was the first mover in the passenger EV market, could feel let down.
Why is Shailesh Chandra, managing director of Tata Motors Passenger Vehicles and Tata Passenger Electric Mobility, not worried about the competition?
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances